HOB Biotech GroupLtd Past Earnings Performance
Past criteria checks 3/6
HOB Biotech GroupLtd's earnings have been declining at an average annual rate of -14%, while the Biotechs industry saw earnings growing at 5.4% annually. Revenues have been growing at an average rate of 10.9% per year. HOB Biotech GroupLtd's return on equity is 5.6%, and it has net margins of 11.4%.
Key information
-14.0%
Earnings growth rate
-21.9%
EPS growth rate
| Biotechs Industry Growth | 11.3% |
| Revenue growth rate | 10.9% |
| Return on equity | 5.6% |
| Net Margin | 11.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Revenue & Expenses Breakdown
How HOB Biotech GroupLtd makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 399 | 46 | 148 | 47 |
| 31 Dec 23 | 394 | 47 | 141 | 46 |
| 30 Sep 23 | 366 | 36 | 137 | 48 |
| 30 Jun 23 | 360 | 39 | 133 | 45 |
| 31 Mar 23 | 325 | 34 | 126 | 41 |
| 31 Dec 22 | 320 | 42 | 119 | 38 |
| 30 Sep 22 | 336 | 56 | 124 | 36 |
| 30 Jun 22 | 321 | 65 | 112 | 34 |
| 31 Mar 22 | 333 | 86 | 103 | 32 |
| 31 Dec 21 | 318 | 86 | 100 | 31 |
| 30 Sep 21 | 314 | 93 | 91 | 27 |
| 30 Jun 21 | 291 | 83 | 85 | 25 |
| 31 Mar 21 | 262 | 75 | 77 | 24 |
| 31 Dec 20 | 222 | 57 | 70 | 23 |
| 30 Sep 20 | 206 | 48 | 71 | 23 |
| 31 Dec 19 | 259 | 64 | 79 | 24 |
| 31 Dec 18 | 201 | 40 | 60 | 23 |
| 31 Dec 17 | 146 | 21 | 49 | 19 |
| 31 Dec 16 | 112 | 4 | 45 | 22 |
Quality Earnings: 688656 has a high level of non-cash earnings.
Growing Profit Margin: 688656's current net profit margins (11.4%) are higher than last year (10.4%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 688656's earnings have declined by 14% per year over the past 5 years.
Accelerating Growth: 688656's earnings growth over the past year (35.4%) exceeds its 5-year average (-14% per year).
Earnings vs Industry: 688656 earnings growth over the past year (35.4%) exceeded the Biotechs industry -3.2%.
Return on Equity
High ROE: 688656's Return on Equity (5.6%) is considered low.